Researchers discovered both immune system and central nervous system dysfunction in animal models and people with ALS4, a genetic, juvenile, and slow-progressing form of ALS.
A new mouse study reveals our sleep position may influence the glymphatic system and could increase the risk of developing ALS or other neurodegenerative diseases.
NU-9, an experimental drug, appears to be more effective at treating ALS than existing medications.
College football players are 5 times more likely to report cognitive impairment, 2.5 times more likely to experience recurrent headaches, and 65% more likely to have cardiovascular problems in their lifetime than their non-football playing peers. Additionally, mortality from brain and other nervous system cancers was 4 times higher in former college football players than the general population.
Nomon, a newly designed flexible system, incorporates probabilistic reasoning to learn how users with motor impairments and paralysis make selections when typing and adjust the interface to improve speed and accuracy.
Mutations in the IL18RAP gene reduce inflammation and appears to protect the brain against ALS.
Study reveals an association between intestinal inflammation and the gut microbiome in the development and progression of ALS.
PolyP, an inorganic polyphosphate released by astrocytes in people with ALS and frontotemporal dementia contributes to the signature motor neuron death associated with the disease pathologies.
Mislocalization of the TDP-43 protein alters the genetic instructions for UNC13A. The findings provide a potential new therapeutic target for the treatment of ALS and frontotemporal dementia.
Measuring the level of neurofilaments in the blood may be a reliable biomarker for the early diagnosis of ALS.
In patients with ALS, astrocytes within the brain become pro-inflammatory and tend to lose their protective function, resulting in changes in the ability to uptake glutamate.
Findings point to microglial TREM2 as a potential target for the treatment of ALS.
